HUP0301341A2 - CCR-3 inhibitor hatású piperidinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények - Google Patents

CCR-3 inhibitor hatású piperidinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0301341A2
HUP0301341A2 HU0301341A HUP0301341A HUP0301341A2 HU P0301341 A2 HUP0301341 A2 HU P0301341A2 HU 0301341 A HU0301341 A HU 0301341A HU P0301341 A HUP0301341 A HU P0301341A HU P0301341 A2 HUP0301341 A2 HU P0301341A2
Authority
HU
Hungary
Prior art keywords
group
alkyl
phenyl
hydrogen atom
substituted
Prior art date
Application number
HU0301341A
Other languages
English (en)
Inventor
Gurdip Bhalay
Trevor John Howe
Darren Mark Le Grand
Thomas Storz
Original Assignee
Novartis Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0017174A external-priority patent/GB0017174D0/en
Priority claimed from GB0023326A external-priority patent/GB0023326D0/en
Application filed by Novartis Ag. filed Critical Novartis Ag.
Publication of HUP0301341A2 publication Critical patent/HUP0301341A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A jelen találmány tárgya az (I) általános képletű vegyületek szabadvagy só formájában, amelyben Ar1 jelentése egy vagy többhalogénatommal helyettesített fenilcsoport, Ar2 jelentése fenil- vagynaftilcsoport, amely helyettesítetlen vagy egy vagy többszubsztituenssel van helyettesítve az alábbiak közül: halogénatom,ciano-, hidroxi-, nitro-, C1-C8-alkil, C1-C8-haloalkil-, C1-C8-alkoxi-, vagy C1-C8-alkoxi-karbonil-csoport, R1 jelentése hidrogénatomvagy adott esetben hidroxi-, C1-C8-alkoxi-, acil-oxi-, -N(R2)R3csoporttal, halogénatommal, karboxi-, C1-C8-alkoxi-karbonil-, -CON(R4)R5 vagy egyértékű ciklusos szerves csoporttal helyettesítettC1-C8-alkil-csoport, R2 és R3 mindegyikének jelentése egymástól függetlenül hidrogénatomvagy C1-C8-alkil-csoport, vagy R2 jelentése hidrogénatom és R3jelentése acil- vagy SO2R6 csoport, vagy R2 és R3 nitrogénatommalegyütt, amelyhez azok kapcsolódnak, 5- vagy 6-tagú heterociklusoscsoportot jelentenek, R4 és R5 mindegyikének jelentése, egymástólfüggetlenül, hidrogénatom vagy C1-C8-alkil-csoport, vagy R4 és R5nitrogénatommal együtt, amelyhez azok kapcsolódnak, 5- vagy 6-tagúheterociklusos csoportot jelentenek, R6 jelentése C1-C8-alkil-, C1-C8-haloalkil-csoport, vagy adott esetben C1-C8-alkil-csoporttalhelyettesített fenilcsoport, és n értéke 1, 2, 3 vagy 4, azzal afeltétellel, hogy amikor Ar1 jelentése p-klór-fenil-csoport és R1jelentése hidrogénatom, Ar1 nem feníl- vagy p-nitro-fenil-csoport. Ajelen találmány szerinti vegyületeket gyógyszerként alkalmazzák. Atalálmány kiterjed a vegyületeket tartalmazó gyógyszerkészítményekreis. Ó
HU0301341A 2000-07-12 2001-07-10 CCR-3 inhibitor hatású piperidinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények HUP0301341A2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0017174A GB0017174D0 (en) 2000-07-12 2000-07-12 Organic compounds
GB0023326A GB0023326D0 (en) 2000-09-22 2000-09-22 Organic compounds
PCT/EP2001/007941 WO2002004420A1 (en) 2000-07-12 2001-07-10 Piperidine coumpounds for use as ccr-3 inhibitors

Publications (1)

Publication Number Publication Date
HUP0301341A2 true HUP0301341A2 (hu) 2003-08-28

Family

ID=26244644

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301341A HUP0301341A2 (hu) 2000-07-12 2001-07-10 CCR-3 inhibitor hatású piperidinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények

Country Status (25)

Country Link
US (1) US6670379B2 (hu)
EP (1) EP1303488B1 (hu)
JP (1) JP2004502756A (hu)
KR (1) KR20030036603A (hu)
CN (1) CN1184204C (hu)
AR (1) AR031597A1 (hu)
AT (1) ATE447553T1 (hu)
AU (2) AU8197201A (hu)
BR (1) BR0112456A (hu)
CA (1) CA2412941C (hu)
CZ (1) CZ200375A3 (hu)
DE (1) DE60140366D1 (hu)
ES (1) ES2334886T3 (hu)
HU (1) HUP0301341A2 (hu)
IL (1) IL153661A0 (hu)
MX (1) MXPA02012848A (hu)
MY (1) MY126139A (hu)
NO (1) NO324760B1 (hu)
NZ (1) NZ523414A (hu)
PE (1) PE20020616A1 (hu)
PL (1) PL358673A1 (hu)
PT (1) PT1303488E (hu)
SK (1) SK272003A3 (hu)
TW (1) TWI227231B (hu)
WO (1) WO2002004420A1 (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19952147A1 (de) * 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US7034042B2 (en) * 2000-10-09 2006-04-25 Novartis Ag N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as CCR33 receptor antagonists
GB0114699D0 (en) 2001-06-15 2001-08-08 Novartis Ag Organic compounds
PL1670482T5 (pl) * 2003-09-16 2022-10-03 Covis Pharma Gmbh Zastosowanie cyklezonidu w leczeniu chorób układu oddechowego
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
TW201524952A (zh) * 2013-03-15 2015-07-01 Araxes Pharma Llc Ｋｒａｓ ｇ１２ｃ之共價抑制劑
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
US10246424B2 (en) 2015-04-10 2019-04-02 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
ES2856880T3 (es) 2015-04-15 2021-09-28 Araxes Pharma Llc Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10858343B2 (en) 2015-09-28 2020-12-08 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10730867B2 (en) 2015-09-28 2020-08-04 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10689356B2 (en) 2015-09-28 2020-06-23 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10647703B2 (en) 2015-09-28 2020-05-12 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356349A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356359B1 (en) 2015-09-28 2021-10-20 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10414757B2 (en) 2015-11-16 2019-09-17 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
EP3519402A1 (en) 2016-09-29 2019-08-07 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
EP3573970A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
EP3573964A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573967A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused hetero-hetero bicyclic compounds and methods of use thereof
WO2018140512A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
CA3063440A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Covalent inhibitors of kras
JP2020521741A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー がんの処置のための化合物およびその使用の方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999004794A1 (en) * 1997-07-25 1999-02-04 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
US6339087B1 (en) 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
PT1131291E (pt) * 1998-11-17 2005-01-31 Hoffmann La Roche Antagonistas iii do receptor 4-aroil-piperidin-ccr-3
US6492400B1 (en) 1998-12-18 2002-12-10 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2000058305A1 (en) * 1999-03-26 2000-10-05 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
US6670379B2 (en) 2003-12-30
KR20030036603A (ko) 2003-05-09
AU8197201A (en) 2002-01-21
US20030176460A1 (en) 2003-09-18
CA2412941C (en) 2011-01-04
BR0112456A (pt) 2003-07-22
WO2002004420A1 (en) 2002-01-17
PL358673A1 (en) 2004-08-09
NO324760B1 (no) 2007-12-10
NO20030135D0 (no) 2003-01-10
ES2334886T3 (es) 2010-03-17
EP1303488A1 (en) 2003-04-23
JP2004502756A (ja) 2004-01-29
AR031597A1 (es) 2003-09-24
NZ523414A (en) 2004-07-30
ATE447553T1 (de) 2009-11-15
CN1184204C (zh) 2005-01-12
TWI227231B (en) 2005-02-01
NO20030135L (no) 2003-02-19
MXPA02012848A (es) 2003-05-15
PE20020616A1 (es) 2002-08-02
SK272003A3 (en) 2003-07-01
CA2412941A1 (en) 2002-01-17
CN1441780A (zh) 2003-09-10
DE60140366D1 (de) 2009-12-17
CZ200375A3 (cs) 2003-04-16
AU2001281972B2 (en) 2004-06-03
IL153661A0 (en) 2003-07-06
EP1303488B1 (en) 2009-11-04
MY126139A (en) 2006-09-29
PT1303488E (pt) 2010-01-19

Similar Documents

Publication Publication Date Title
HUP0301341A2 (hu) CCR-3 inhibitor hatású piperidinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0300565A2 (hu) PDE 5 inhibitor hatású 8-kinolin-xantin- és 8-izo-kinolin-xantin-származékok, alkalmazásuk, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0300203A2 (en) Novel cyclic amide derivatives, and pharmaceutical compositions containing same
HUP0303756A2 (hu) 1-Aril- vagy 1-alkilszulfonil-heterociklobenzazolok és eljárás ezek elõállítására és ezeket tartalmazó gyógyszerkészítmények
HUP0400704A2 (hu) Heterociklusos éterrel szubsztituált imidazokinolinok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
RU95108387A (ru) Дикетопиперазин, способ его получения, фармацевтическая композиция, применение дикетопиперазина
HUP0100431A2 (hu) Adamantánszármazékok, ezeket tartalmazó gyógyászati készítmények és előállításuk
HUP0001848A2 (hu) NOS gátló 6-fenil-piridil-2-amin származékok
HUP0300350A2 (hu) Új 3-amino-azetidin-származékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények
HUP0001498A2 (hu) Farnezil-transzferáz-gátló 1,8-anellált imidazolil-kinolinon-származékok, intermedierjeik, a vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
HUP0400887A2 (hu) Glikopeptidszármazékok és ezeket tartalmazó gyógyászati kompozíciók
HUP0301117A2 (hu) Imidazolszármazék kináz inhibitorok, alkalmazásuk, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0301404A2 (hu) Azetidinszármazékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények és eljárás a vegyületek előállítására
HUP0202810A2 (hu) Szubsztituált 2-tio-3.5-diciano-4-aril-6-aminopiridinek és eljárás az előállításukra, valamint ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
EA200401607A1 (ru) Ингибиторы в отношении активации ap-1 и nfat
DK490288A (da) Substituerede thiazolidindionderivater
HUP0402507A2 (hu) N(fenilszulfonil)glicin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyászati készítmények
HUP9700811A2 (hu) Kondenzált vázas tetrahidropiridin-N-hidroxi-karboxamid-származékok, ezeket tartalmazó gyógyászati készítmények és eljárás a vegyületek előállítására
HUP0300838A2 (hu) Új heteroarilszármazékok, eljárás az előállításukra és gyógyszerként való alkalmazásuk
HUP0401009A2 (hu) 5-Hidroxitriptamin-6-ligandumokként alkalmazható 1-aril- vagy 1- alkil-szulfonilbenzazol-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0300080A2 (hu) Új malonsavszármazékok, eljárás előállításukra, ezek alkalmazása Xa faktor inhibitorként és ezeket tartalmazó gyógyszerkészítmények
HUP0101688A2 (hu) Heterociklussal szubsztituált amidok és alkalmazásuk gyógyszerkészítmények előállítására
CY1107677T1 (el) Παραγωγα της 1-[indol-3-yl)carbonyl]piperazine
HUP0001758A2 (hu) C-terminálison karbonil és heterociklusos funkciós csoportokkal rendelkező dolasztatin-15-származékok, ezeket hatóanyagként tartalmazó gyógyászati készítmények és alkalmazásuk
HUP0402235A2 (hu) 4,4-Difluor-1,2,3,4-tetrahidro-5H-1-benzazepin-származékok és ezek sói és ezeket tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished